Seoul National University Hospital
- Country
- 🇰🇷South Korea
- Ownership
- Private
- Established
- 2003-01-01
- Employees
- 501
- Market Cap
- -
- Website
- https://www.snubh.org
Clinical Trials
2.9k
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2363 trials with phase data)• Click on a phase to view related trials
EOI Block for Laparoscopic Gastrostomy
- Conditions
- Gastrostomy
- First Posted Date
- 2025-08-13
- Last Posted Date
- 2025-08-13
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT07119346
- Locations
- 🇰🇷
Seoul National University Children's Hospital, Seoul, Korea, Republic of
SWEEP: Shuttle Walking Test for Exercise Evaluation in Pulmonary Resection
- Conditions
- COPDILDBronchiectasisLung Cancer NOSDyspnea During Activity
- First Posted Date
- 2025-08-04
- Last Posted Date
- 2025-08-04
- Lead Sponsor
- Seoul National University Bundang Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT07102589
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam Si, Not Required For This Country, Korea, Republic of
Efficacy of Stromal Vascular Fraction on Acne Scar Correction
- Conditions
- Acne ScarsAcne Scars - Atrophic
- Interventions
- Biological: stromal vascular fraction (SVF)Other: Normal Saline (NS)
- First Posted Date
- 2025-07-31
- Last Posted Date
- 2025-07-31
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 16
- Registration Number
- NCT07094958
Topical Icariin on Acne and Acne Scars
- Conditions
- AcneAcne Scars
- Interventions
- Drug: Vehicle Control
- First Posted Date
- 2025-07-22
- Last Posted Date
- 2025-07-22
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 25
- Registration Number
- NCT07076784
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Intraoperative Pathologic Evaluation of Central Lymph Nodes in Papillary Thyroid Carcinoma
- Conditions
- Thyroid Cancer, Papillary
- First Posted Date
- 2025-07-15
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 509
- Registration Number
- NCT07066644
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of
- Prev
- 1
- 2
- 3
- 4
- 5
- 433
- Next
News
Seer Launches Next-Generation Proteomics Platform Enabling Unprecedented 20,000-Sample Cancer Study
Seer's new Proteograph ONE Assay and SP200 Automation Instrument can process over 1,000 samples per week, doubling throughput while reducing per-sample costs by approximately 60% compared to 2021.
Huonslab Completes Enrollment in Phase 1 Trial for Recombinant Hyaluronidase, Eyes 2025 Regulatory Filing
Huonslab has completed patient enrollment in its pivotal Phase 1 clinical trial of HLB3-002 (Hydizyme™), a recombinant human hyaluronidase, with 243 healthy volunteers across four leading South Korean medical centers.
GemVax's GV1001 Receives FDA Fast Track Designation and Korean Therapeutic Use Approval for Progressive Supranuclear Palsy
GV1001, developed by GemVax & KAEL, has received both FDA Fast Track designation and Korean Ministry of Food and Drug Safety approval for therapeutic use in progressive supranuclear palsy patients.
Hanmi Pharmaceutical Partners with MSD to Test Novel Bispecific Antibody BH3120 in Combination with KEYTRUDA
Hanmi Pharmaceutical has entered a Clinical Trial Collaboration and Supply Agreement with MSD to evaluate its novel immunotherapy BH3120 in combination with KEYTRUDA for patients with progressive or metastatic solid tumors.